Gilead’s Shares Rally on 129.88% Volume Spike, Ranked 33rd in Market Activity

On September 8, 2025, , , , ranking 33rd in market activity.

Gilead is advancing its HIV prevention initiatives through a partnership with PEPFAR to distribute lenacapavir, a twice-yearly HIV treatment, to up to two million individuals in low- and middle-income countries. , signaling strategic focus on expanding cell therapy capabilities.

Analyst activity highlights include a "Moderate Buy" rating from MarketBeat and a "Strong-Buy" upgrade from Daiwa America. Institutional investors, including Resolute Capital and Allstate Corp, have increased stakes, while others like APG Asset Management and Channing Capital have reduced holdings. These moves reflect divergent views on Gilead’s growth trajectory amid its recent therapeutic advancements.

Backtesting parameters for a cross-sectional volume strategy would involve the U.S. common equity universe (NYSE, NASDAQ, AMEX), equal-weighted positions across 500 stocks, and a 1-day holding period. Transaction costs are excluded in the frictionless model. Execution would begin from January 3, 2022, to generate performance metrics.